RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA

B. A.J. Ponder; R. Coffey; R. F. Gagel; P. Semple; M. A. Ponder; M. E. Pembrey; M. Telenius-Berg; D. F. Easton; Research Campaign Medullary Thyroid Group Cancer Research Campaign Medullary Thyroid Group

doi:10.1016/S0140-6736(88)91191-9

RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA

B. A.J. Ponder
, R. Coffey
, R. F. Gagel
, P. Semple
, M. A. Ponder
, M. E. Pembrey
, M. Telenius-Berg
, D. F. Easton
, Research Campaign Medullary Thyroid Group Cancer Research Campaign Medullary Thyroid Group

Research output: Contribution to journal › Article › peer-review

155 Scopus citations

Abstract

Many gene carriers for multiple endocrine neoplasia type 2a (MEN 2a) do not manifest the disease, even into old age. Thus, a negative family history in a patient presenting with medullary thyroid carcinoma does not reliably exclude familial disease. Data are reported for the probability that the MEN 2a gene will either have manifested clinically or be detectable by stimulated calcitonin screening by a given age. These probabilities can be used to calculate individual risks and to guide screening.

Original language	English (US)
Pages (from-to)	397-401
Number of pages	5
Journal	The Lancet
Volume	331
Issue number	8582
DOIs	https://doi.org/10.1016/S0140-6736(88)91191-9
State	Published - Feb 20 1988
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(88)91191-9

Cite this

@article{3feed3d2de2c409da5982eabc9f81034,

title = "RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA",

abstract = "Many gene carriers for multiple endocrine neoplasia type 2a (MEN 2a) do not manifest the disease, even into old age. Thus, a negative family history in a patient presenting with medullary thyroid carcinoma does not reliably exclude familial disease. Data are reported for the probability that the MEN 2a gene will either have manifested clinically or be detectable by stimulated calcitonin screening by a given age. These probabilities can be used to calculate individual risks and to guide screening.",

author = "Ponder, \{B. A.J.\} and R. Coffey and Gagel, \{R. F.\} and P. Semple and Ponder, \{M. A.\} and Pembrey, \{M. E.\} and M. Telenius-Berg and Easton, \{D. F.\} and \{Cancer Research Campaign Medullary Thyroid Group\}, \{Research Campaign Medullary Thyroid Group\}",

note = "Funding Information: Council and CRC to the Institute of Cancer Research. R. G. receives support from NIH grant AG 31307 and a VA merit review. M. T.-B. is supported by the Swedish Medical Research Council. Funding Information: This work was supported by grants from the Cancer Research Campaign to the CRC Medullary Thyroid Group, and from the Medical Research",

year = "1988",

month = feb,

day = "20",

doi = "10.1016/S0140-6736(88)91191-9",

language = "English (US)",

volume = "331",

pages = "397--401",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8582",

}

TY - JOUR

T1 - RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA

AU - Ponder, B. A.J.

AU - Coffey, R.

AU - Gagel, R. F.

AU - Semple, P.

AU - Ponder, M. A.

AU - Pembrey, M. E.

AU - Telenius-Berg, M.

AU - Easton, D. F.

AU - Cancer Research Campaign Medullary Thyroid Group, Research Campaign Medullary Thyroid Group

N1 - Funding Information: Council and CRC to the Institute of Cancer Research. R. G. receives support from NIH grant AG 31307 and a VA merit review. M. T.-B. is supported by the Swedish Medical Research Council. Funding Information: This work was supported by grants from the Cancer Research Campaign to the CRC Medullary Thyroid Group, and from the Medical Research

PY - 1988/2/20

Y1 - 1988/2/20

N2 - Many gene carriers for multiple endocrine neoplasia type 2a (MEN 2a) do not manifest the disease, even into old age. Thus, a negative family history in a patient presenting with medullary thyroid carcinoma does not reliably exclude familial disease. Data are reported for the probability that the MEN 2a gene will either have manifested clinically or be detectable by stimulated calcitonin screening by a given age. These probabilities can be used to calculate individual risks and to guide screening.

AB - Many gene carriers for multiple endocrine neoplasia type 2a (MEN 2a) do not manifest the disease, even into old age. Thus, a negative family history in a patient presenting with medullary thyroid carcinoma does not reliably exclude familial disease. Data are reported for the probability that the MEN 2a gene will either have manifested clinically or be detectable by stimulated calcitonin screening by a given age. These probabilities can be used to calculate individual risks and to guide screening.

UR - https://www.scopus.com/pages/publications/0023858139

UR - https://www.scopus.com/pages/publications/0023858139#tab=citedBy

U2 - 10.1016/S0140-6736(88)91191-9

DO - 10.1016/S0140-6736(88)91191-9

M3 - Article

C2 - 2893198

AN - SCOPUS:0023858139

SN - 0140-6736

VL - 331

SP - 397

EP - 401

JO - The Lancet

JF - The Lancet

IS - 8582

ER -

RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this